Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Active Inflammatory Bowel Disease
Information source: University of Aarhus
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Inflammatory Bowel Diseases
Phase: N/A
Status: Completed
Sponsored by: University of Aarhus Official(s) and/or principal investigator(s): Karen Louise Thomsen, MD, Principal Investigator, Affiliation: Aarhus University Hospital
Summary
Loss of total mass of muscles (catabolism) is a serious clinical problem in patients with
active inflammatory bowel disease (IBD). The investigators have earlier shown that the liver
plays an important role in this stress-catabolism by increasing the production of urea
during the inflammatory process.
The purpose of this study is to examine the effect of the anti-inflammatory drugs
prednisolone and infliximab on the regulation of the urea synthesis in patients with active
ulcerative colitis and Crohn's disease.
Clinical Details
Official title: Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Patients With Active Ulcerative Colitis and Crohn's Disease
Study design: Observational Model: Case-Crossover, Time Perspective: Prospective
Primary outcome: Functional Hepatic Nitrogen Clearance
Secondary outcome: Clinical and biochemical measures of inflammation
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Moderate to severe active inflammatory bowel disease
Exclusion Criteria:
- Viral or bacterial infections
- Other chronical inflammatory diseases
- Cancer
- Other catabolic diseases
- Treatment with prednisolone or infliximab within the last 8 weeks
Locations and Contacts
Department of Medicine V, Aarhus University Hospital, Aarhus 8000, Denmark
Additional Information
Starting date: January 2009
Last updated: October 11, 2012
|